- Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
-
van Rheenen H, van Rheenen PF
- KMID: 2471621
- Pediatr Gastroenterol Hepatol Nutr.
- 2020 Mar;23(2):121-131.
- doi: 10.5223/pghn.2020.23.2.121
PURPOSE: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- History and Future of Treatment for Acute Stage Kawasaki Disease
-
Ishii M, Ebato T, Kato H
- KMID: 2468036
- Korean Circ J.
- 2020 Feb;50(2):112-119.
- doi: 10.4070/kcj.2019.0290
Kawasaki disease is a form of vasculitis, mainly in small and medium arteries of unknown origin, occurring frequently in childhood. It is the leading form of childhood-onset acquired heart disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
-
Han M, Jung YS, Cheon JH, Park S
- KMID: 2466335
- Yonsei Med J.
- 2020 Jan;61(1):48-55.
- doi: 10.3349/ymj.2020.61.1.48
PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with ulcerative colitis (UC) are extremely limited, especially in the Asian population. We compared clinically important... -
- CITED
-
- Close
- SHARE
-
- Close
- Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
-
Park SK, Moon W, Kim ES, Park SH, Park DI
- KMID: 2469908
- Korean J Gastroenterol.
- 2019 Dec;74(6):333-340.
- doi: 10.4166/kjg.2019.74.6.333
BACKGROUND/AIMS: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn's and Colitis Organization (ECCO) members in 2013 and 2015.... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
-
Lee S, Park YJ, Lee JY
- KMID: 2461174
- J Korean Med Sci.
- 2019 Nov;34(42):e278.
- doi: 10.3346/jkms.2019.34.e278
BACKGROUND: Tumor necrosis factor-alpha (TNF-α) inhibitors (TNFis), which are the main treatment for ankylosing spondylitis (AS), have been reported not only to reduce the incidence of anterior uveitis (AU) but... -
- CITED
-
- Close
- SHARE
-
- Close
- Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
-
Nakagawa T, Kobayashi , Nishikawa , Yamada F, Asai S, Sameshima , Suzuki Y, Watanabe M, Hibi T
- KMID: 2465816
- Intest Res.
- 2019 Oct;17(4):504-515.
- doi: 10.5217/ir.2019.00030
BACKGROUND/AIMS: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. METHODS: Patients were prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of a Seton Procedure Combined With Infliximab Therapy (Early vs. Late) in Perianal Fistula With Crohn Disease
-
Jeon M, Song K, Koo J, Kim S
- KMID: 2464339
- Ann Coloproctol.
- 2019 Oct;35(5):249-253.
- doi: 10.3393/ac.2018.11.23.1
PURPOSE: We assessed the clinical outcomes of a seton procedure combined with early versus late institution of infliximab (IFX) therapy. METHODS: This retrospective study comprised 76 patients who underwent surgery for... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Affecting Surgical Treatment With Infliximab Therapy in Perianal Fistula With Crohn Disease
-
Lee JL
- KMID: 2464334
- Ann Coloproctol.
- 2019 Oct;35(5):225-226.
- doi: 10.3393/ac.2019.10.11
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
-
Jun YK, Chun J, Kang EA, Lee HJ, Im JP, Kim JS
- KMID: 2458698
- Korean J Gastroenterol.
- 2019 Sep;74(3):168-174.
- doi: 10.4166/kjg.2019.74.3.168
Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis (UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
-
Choi SY, Kang B, Choe YH
- KMID: 2458511
- Gut Liver.
- 2019 Sep;13(5):541-548.
- doi: 10.5009/gnl18129
BACKGROUND/AIMS: Infliximab (IFX) often loses its therapeutic effect in initial responders with inflammatory bowel disease (IBD) over time. Low serum IFX trough levels (TLs) are linked to poor clinical response... -
- CITED
-
- Close
- SHARE
-
- Close
- Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
-
Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia G, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu , Yang SK, Ouyang Q, Geary R, De Silva J, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW, on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis
- KMID: 2454738
- Intest Res.
- 2019 Jul;17(3):285-310.
- doi: 10.5217/ir.2019.00026
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease
-
Woo MH, Cho YH, Sohn MJ, Lee EJ, Kim JW, Moon JS, Ko JS, Kim HY
- KMID: 2451576
- Pediatr Gastroenterol Hepatol Nutr.
- 2019 Jul;22(4):358-368.
- doi: 10.5223/pghn.2019.22.4.358
PURPOSE: Pediatric Crohn's disease (CD) is directly related to growth and has a high probability of requiring surgical intervention(s); therefore, more active treatment for CD is required for children. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Infliximab-Induced Lupus in Crohn's Disease
-
Choi SJ, Kim S, Kim HY, Lee Y, Hyun DG, Yang SK, Kim YG
- KMID: 2449430
- Korean J Med.
- 2019 Jun;94(3):303-307.
- doi: 10.3904/kjm.2019.94.3.303
Infliximab (IFX) is an anti-tumor necrosis factor (TNF) monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Rarely, anti-TNF-induced lupus (ATIL) may occur. ATIL differs from classical... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of severe hidradenitis suppurativa with biologic therapy and wide excision
-
Lim SY, Cheong EC, Oon HH
- KMID: 2450939
- Arch Plast Surg.
- 2019 May;46(3):272-276.
- doi: 10.5999/aps.2018.00339
Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of... -
- CITED
-
- Close
- SHARE
-
- Close
- Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature
-
Choi YS, Kim JK, Kim WJ, Kim MJ
- KMID: 2449969
- Intest Res.
- 2019 Apr;17(2):273-277.
- doi: 10.5217/ir.2018.00122
Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes... -
- CITED
-
- Close
- SHARE
-
- Close
- Infliximab, Is It Really a New Horizon for the Treatment of Kawasaki Disease?
-
Eun LY
- KMID: 2432138
- Korean Circ J.
- 2019 Feb;49(2):192-193.
- doi: 10.4070/kcj.2018.0460
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
-
Hur G, Song MS, Sohn S, Lee HD, Kim GB, Cho HJ, Yoon KL, Joo CU, Hyun MC, Kim CH
- KMID: 2432137
- Korean Circ J.
- 2019 Feb;49(2):183-191.
- doi: 10.4070/kcj.2018.0214
BACKGROUND AND OBJECTIVES: We investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
-
Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T
- KMID: 2438448
- Intest Res.
- 2019 Jan;17(1):94-106.
- doi: 10.5217/ir.2018.00048
BACKGROUND/AIMS: Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease
-
Park J, Cheon JH
- KMID: 2427452
- Gut Liver.
- 2018 Nov;12(6):623-632.
- doi: 10.5009/gnl17462
Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult... -
- CITED
-
- Close
- SHARE
-
- Close
- A Pediatric Case of Inflammatory Bowel Disease with Renal Amyloidosis
-
Hyun H, Park E, Kim JH, Cho MH, Kang HG, Moon JS, Moon KC, Ha IS, Cheong HI
- KMID: 2435376
- Child Kidney Dis.
- 2018 Oct;22(2):81-85.
- doi: 10.3339/jkspn.2018.22.2.81
Amyloidosis is a rare disease that results from the deposition of extracellular protein in various body tissues, causing progressive organ dysfunction. Secondary renal amyloidosis is a rare but serious complication... -
- CITED
-
- Close
- SHARE
-
- Close
